- Home
- OABI vs JMIA Comparison
OABI vs JMIA Comparison
Compare OABI & JMIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- JMIA
- Stock Information
- Founded
- OABI 2012
- JMIA 2012
- Country
- OABI United States
- JMIA Germany
- Employees
- OABI N/A
- JMIA N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- JMIA Catalog/Specialty Distribution
- Sector
- OABI Health Care
- JMIA Consumer Discretionary
- Exchange
- OABI Nasdaq
- JMIA Nasdaq
- Market Cap
- OABI 490.1M
- JMIA 573.4M
- IPO Year
- OABI N/A
- JMIA 2019
- Fundamental
- Price
- OABI $3.50
- JMIA $4.03
- Analyst Decision
- OABI Strong Buy
- JMIA Buy
- Analyst Count
- OABI 4
- JMIA 3
- Target Price
- OABI $9.00
- JMIA $6.53
- AVG Volume (30 Days)
- OABI 484.9K
- JMIA 4.3M
- Earning Date
- OABI 11-12-2024
- JMIA 02-13-2025
- Dividend Yield
- OABI N/A
- JMIA N/A
- EPS Growth
- OABI N/A
- JMIA N/A
- EPS
- OABI N/A
- JMIA N/A
- Revenue
- OABI $20,409,000.00
- JMIA $181,204,000.00
- Revenue This Year
- OABI N/A
- JMIA $3.80
- Revenue Next Year
- OABI $77.16
- JMIA $5.50
- P/E Ratio
- OABI N/A
- JMIA N/A
- Revenue Growth
- OABI N/A
- JMIA 3.61
- 52 Week Low
- OABI $3.43
- JMIA $2.88
- 52 Week High
- OABI $6.72
- JMIA $15.04
- Technical
- Relative Strength Index (RSI)
- OABI 32.80
- JMIA 44.72
- Support Level
- OABI $3.43
- JMIA $4.22
- Resistance Level
- OABI $4.17
- JMIA $4.74
- Average True Range (ATR)
- OABI 0.16
- JMIA 0.43
- MACD
- OABI -0.05
- JMIA -0.02
- Stochastic Oscillator
- OABI 9.46
- JMIA 24.32
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.